Cantor analyst Elemer Piros reiterated a Buy rating on shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) with a price target of $17, after the …
Investors in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) should be smiling from ear to ear today after the drug maker announced positive topline results …
For those wondering why Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) shares are presently taking a 25% nosedive, look no further than The Street blogger …